UseGrants

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

National Institutes of HealthUp to $1,000,000Due May 7, 2028
View & apply on Grants.gov →

Open to U.S. universities, research institutions, nonprofits, foreign organizations, and certain government/tribal entities. This NIH R01 funds preclinical mouse-model testing of repurposed or inve…

Deadline
May 7, 2028
Posted
Dec 30, 2024
Award amount
Up to $1,000,000
Focus areas
Health

Don’t miss this deadline

We’ll email you before May 7, 2028 so you have time to apply.

In plain English

Open to U.S. universities, research institutions, nonprofits, foreign organizations, and certain government/tribal entities. This NIH R01 funds preclinical mouse-model testing of repurposed or investigational drugs — alone or with non-drug interventions — for Alzheimer's disease and related dementias. Awards up to about $1,000,000.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this grant

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit

Related grants

Other open grants funding Health — soonest deadline first.

Also listed under National Institutes of Health and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.